The AYAME study, initiated in May 2018, is a placebo-controlled, double-blind, Phase 3 clinical study assessing the efficacy and safety of bardoxolone methyl in more than 1,000 Japanese patients with stages G3 and G4 DKD without elevated BNP or a history of heart failure. Here, NPPB is linked to heart failure.